CD274 and non-small cell lung carcinoma: In the updated analysis of KEYNOTE-024 [59], pembrolizumab continues to show an OS benefit as first-line therapy for advanced NSCLC with PD-L1 TPS of ≥50% compared to platinum-based chemotherapy (hazard ratio (HR): 0.63; 95% CI: 0.47 to 0.86; nominal p = 0.002).